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Background: Microalbuminuria has been shown to be a risk factor for cardiovascular and renal disease in patients
with hypertension and diabetes as well as in the general population. Urinary albumin excretion over 24 h is
considered a ‘gold standard’ to detect microalbuminuria. Few studies have used 24-h urinary albumin excretion to
analyze the prevalence of and related factors for microalbuminuira in a general Chinese population.
Methods: This study included 1980 adults aged 18–69 years from the Shandong-Ministry of Health Action on
Salt and Hypertension (SMASH) Project 2011 survey. Blood pressure, height, weight and waist circumference
were measured, and a venous blood and timed 24-h urine samples were collected from each participant. Linear
and logistic regression analyses were used to test associations between established cardiovascular risk factors
and microalbuminuria.
Results: The median (25th–75th percentile) of 24-h urinary albumin excretion was 6.1 mg/d (4.5–8.7 mg/d) for
all adults, 6.0 mg/d (4.4–8.5 mg/d) for men and 6.2 mg/d (4.6–8.9 mg/d) for women. The overall prevalence of
microalbuminuria was 4.1% (95% confidence interval [CI]: 3.2–5.0%), 3.7% (95% CI: 2.9–4.5%) for men and 4.6%
(95% CI: 3.7–5.5%) for women. Microalbuminuria was present in 8.1% (95% CI: 6.9–9.3%) of individuals with hypertension,
11.4% (95% CI: 10.0–12.8%) of those with diabetes and 15.6% (95% CI: 14.0–17.2%) of those with both. Multiple
logistic regression analysis indicated that systolic blood pressure (odds ratio [OR] 1.02; 95% CI: 1.01–1.03) and
fasting blood glucose (OR 1.19; 95% CI: 1.05–1.35) were the independent risk factors for microalbuminuria.
Conclusions: Adults in the general population of Shandong Province have a moderate prevalence of
microalbuminuria. Those with hypertension and diabetes are at high risk of having microalbuminuria,
suggesting the need for screening and early intervention for microalbuminuria among these individuals.
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Microalbuminuria (MAU), an abnormal increase in the
urinary excretion of albumin, is a risk factor for cardio-
vascular and renal disease in patients with hypertension
and diabetes [1-4]. Early intervention for MAU among
the patients with hypertension and diabetes has been
shown to reduce their risks of progression of renal and* Correspondence: linhong@chinawch.org.cn
1National Center for Chronic and Noncommunicable Disease Control and
Prevention, Chinese Center for Disease Control and Prevention, Beijing
100050, China
Full list of author information is available at the end of the article
© 2014 Yan et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cardiovascular complications [5,6]. International guidelines
therefore recommend that patients with hypertension and
diabetes be screened for MAU, enhancing the benefits of
early diagnosis and treatment [7,8].
MAU has also been shown to be predictive of cardio-
vascular events and all cause mortality in the general
population [9-11]. In middle-aged to elderly-aged Chinese
adults, the risk of cardiovascular mortality is about three-
fold higher in individuals with than without MAU [9].
Additionally, MAU was independently associated with
other cardiovascular risk factors [12,13]. Screening for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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undiagnosed cardiovascular disease [13,14].
The amount of urinary albumin excreted over a 24-h
period is considered the ‘gold standard’ for defining
MAU [3]. However, owing to the inconvenience and
cumbersomeness of 24-h urine collection, spot urine
measurements of albumin concentration or albumin to
creatinine ratio are used as alternatives in clinical prac-
tice [15-17]. Indeed, the previous studies of MAU in
Chinese adults were assessed using the alternative
methods, not by measuring 24-h urinary albumin excre-
tion. This study therefore assessed the prevalence of
MAU in a general Chinese population by analyzing 24-h
urine secretion, as well as analyzing the association be-
tween MAU and established risk factors for cardiovascu-
lar disease.Methods
Subjects
The study subjects had participated in the Shandong-
Ministry of Health Action on Salt and Hypertension
(SMASH) project 2011 survey; the methods used for
this survey have been described in detail [18]. Using a
stratified multi-stage cluster sampling method, 2112
adults aged 18–69 years were selected from 20 coun-
ties and districts across Shandong Province. All the
participants were required to complete a face-to-face
questionnaire survey, undergo an anthropometric exam-
ination and provide fasting blood and timed 24-h urine
samples. This study was conducted according to the
guidelines of the Declaration of Helsinki, and all proce-
dures involving human subjects were approved by the
Ethics Committee of the Shandong Center for Disease
Control and Prevention. Written informed consent was
obtained from each subject.Anthropometric measurements
Physical examinations, including measurements of height,
weight, waist circumference and blood pressure, were
performed by trained health professionals. Weight was
measured barefoot and in light-clothing. Body mass
index (BMI) was calculated as weight in kilograms
divided by the square of height in meters. Under-
weight, normal weight, overweight and obesity were
defined as BMI < 18.5 kg/m2, ≥18.5 but <24 kg/m2, ≥24
but <28 kg/m2 and ≥28 kg/m2 respectively according to
Chinese guidelines [19].
Blood pressure was measured in a sitting position three
times every 5 min on one occasion using an electronic
sphygmomanometer (HEM-7071, Omron Corporation,
Japan), with the average of the three measures defined
as individual blood pressure. Hypertension was defined
as systolic blood pressure (SBP) ≥140 mmHg or diastolicblood pressure (DBP) ≥90 mmHg, or self-reported taking
of anti-hypertensive medications [20].
Blood sample collection and biochemical assays
A morning sample of venous blood was drawn from
each participant and centrifuged within 2 h of collection.
Participants with fasting blood glucose ≥ 6.1 mmol/L
were invited to return for an oral glucose tolerance test
(OGTT) on another day, at which time 2 h postload
blood glucose (2hPBG) was tested.
Serum samples were frozen at −80°C. All blood and
24-h urine sample were assessed by ADICON Clinical
Laboratory Inc., Jinan, Shandong. Serum glucose, total
cholesterol, high-density lipoproteins, low-density lipo-
proteins and triglycerides were measured by standard
laboratory methods on an Olympus AU640.
Diabetes was diagnosed according to the standard of the
American Diabetes Association (2003) [21]. Participants
were defined as having type 2 diabetes if they had fasting
serum glucose ≥7.0 mmol/L, 2hPBG ≥11.1 mmol/L, or
validated history of diabetes as diagnosed by a phys-
ician. Dyslipidaemia was defined as elevated serum
concentrations of total cholesterol (TC) ≥6.1 mmol/L,
and/or triacylglycerol (TG) ≥ 2.26 mmol/L, and/or LDL-
cholesterol (LDL-C) ≥4.14 mmol/L, and/or a decreased
HDL-cholesterol (HDL-C) concentration of <1.0 mmol/L
as described by the American National Cholesterol Educa-
tion Program (Adult Treatment Panel III) [22].
24-h urine collection and measurements
Participants were instructed on the methods of collec-
tion of a standard 24-hour urine sample. Each partici-
pant was given a standard plastic container containing
about 1 g boric acid as a preservative. Participants were
instructed to discard the first void and collect all the
urine during the following 24 h in the container. A local
health professional recorded the starting and ending
times of each collection and determined the exact dur-
ation of collection. Each participant was interviewed
using a standard questionnaire to assess the complete-
ness of urine collection. Urine volume was measured on
a standard platform at each field site by a laboratory
technician. The collected urine samples were kept in a
freezer at −20°C and were delivered to ADICON Clinical
Laboratory Inc for laboratory testing. Individual urinary
albumin and creatinine excretion were calculated as the
products of their concentrations in the urine and urinary
volume, corrected to 24 h.
Evaluation of albuminuria
Urinary creatinine excretion was assessed using the picric
acid method, and 24-h urinary albumin excretion (UAE)
was assessed using an immunonephelometric method,
both on an Olympus AU640 Analyzer. The albumin to








Age (years) 41.4 ± 14.2 41.4 ± 13.6 41.4 ± 14.0 0.76
Current smoking,% 47.4 2.7 26.1 <0.001
BMI (kg/m2) 24.5 ± 3.9 24.5 ± 3.9 24.5 ± 3.9 0.94
Waist circumference (cm) 85.5 ± 11.4 81.6 ± 10.8 83.7 ± 11.3 <0.001
Blood pressure
SBP (mmHg) 124.7 ± 17.9 118 ± 19.2 121.5 ± 18.8 <0.0001
DBP (mmHg) 80.5 ± 11.5 77.1 ± 11.2 78.9 ± 11.5 <0.0001
Serum FBG (mmol) 5.5 ± 1.2 5.5 ± 1.1 5.5 ± 1.1 0.50
Dyslipidemia,% 28.0 18.8 23.6 <0.0001
TC (mmol) 4.4 ± 0.9 4.4 ± 1.0 4.4 ± 0.9 0.74
High TC,% 3.8 4.1 3.9 0.60
HDLC (mmol) 1.4 ± 0.4 1.5 ± 0.3 1.4 ± 0.3 0.10
Low HDL,% 14.6 8.3 11.3 <0.0001
LDLC (mmol) 2.2 ± 0.6 2.2 ± 0.6 2.2 ± 0.6 0.30
High LDL,% 0.6 1.0 0.8 0.33
TG (mmol) 1.6 ± 1.9 1.2 ± 1.1 1.4 ± 1.6 <0.001
High TG,% 15.8 10.7 13.4 0.0008
Hypertension,% 25.0 22.2 23.7 0.15
Diabetes,% 5.8 6.7 6.2 0.40
Obese,% 17.6 18.0 17.8 0.81
Urinary excretion
Volume (ml/d) 1582 ± 660 1501 ± 587 1544 ± 627 0.004
Creatinine (mmol/d) 9.8 ± 3.3 7.5 ± 2.2 8.7 ± 3.1 <0.001
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agreements between albuminuria as determined by
UAE and by ACR. For UAE, <30 mg/d, 30–299 mg/d
and ≥300 mg/d were defined as normal, microalbumi-
nuria and macroalbuminuria. The corresponding value
for ACR was <30 mg/g, 30–299 mg/g and ≥300 mg/g,
respectively.
Each 24-h urine sample was assessed for completeness
using urinary volume and gender specific urinary creatin-
ine cut-off point. Incompleteness was defined as 24-h urin-
ary volume < 500 ml, and/or 24-h urinary creatinine < 1.91
or >18.27 mmol in men, or < 1.36 or >14.28 mmol in
women, with these samples excluded from analysis.
Of the 2112 participants, 88 provided incomplete 24-h
urine collection, and 44 failed to provide the blood sample.
Thus, the study involved 1980 participants.
Statistical analysis
Normally distributed and continuous variables were
expressed as mean ± standard deviation (SD), and the
differences between gender were assessed by t test.
Mean and percentile values (i.e. P5, P25, P50, P75
and P95) of 24-h UAE were analyzed. The prevalence
of microalbuminuria was reported as a percentage
with 95% confidence intervals (CI). Of the 1980 par-
ticipants, only two were classified as having macroal-
buminuria, therefore, only factors associated with the
prevalence of microalbuminuria were analyzed with differ-
ences between the proportions of subjects with microalbu-
minuria assessed by Fisher’s Exact test or the Chi-square
test. Agreement in the classification of albuminuria by
measurements of UAE and ACR was summarized by
Cohen’s k [23].
Two methods were used for multiple regression ana-
lysis. First, a stepwise multiple linear regression analysis
was performed. Because UAE was not normally distrib-
uted, log(n)UAE was considered the dependent variable,
with age, gender, smoking (yes/no), BMI, SBP(mmHg),
FBG(mmol/l) and TC(mmol/l) considered independent
variables. The regression model also analyzed HDL-C,
LDL-C and TG concentrations as covariates. Second,
multiple stepwise logistic regression analysis was per-
formed to assess factors associated with microalbumi-
nuria. The dependent variable was microalbuminuria
(yes/no), with the covariates the same as those described
above.
Statistical analyses were performed with SAS 9.3 (SAS
Institute Inc., Cary, North Carolina, USA). A P value < 0.05
was considered statistically significant.
Results
Clinical characteristics of the study population
Out of the 1980 participants, 52.4% were male, and
their average age was 41 years old (SD = 14.0 years).Approximately 25% of the participants were hypertensive,
with a median (Q1–Q3) hypertension duration of 3.0
(1.3–7.5) years. About 6.2% had diabetes, and 23.6% had
dyslipidaemia. The average BMI was 24.5 kg/m2 and
17.8% of the participants were obese (Table 1).
Distribution of 24-h UAE
The overall median (P25-P75) 24-h UAE was 6.1 (4.5–
8.7) mg/d, 6.0 (4.4–8.5) mg/d for men and 6.2 (4.6–8.9)
mg/d for women. The median (P25-P75) 24-h UAEs
among subjects with hypertension and diabetes were 6.7
(4.8–10.8) mg/d and 7.6 (5.3–11.3) mg/d respectively
(Table 2).
Prevalence of microalbuminuria
The prevalence of MAU among general Shandong adults
was 4.1% (95% CI: 3.2–5.0%), 3.7% (95% CI: 2.9–4.5%)
for men and 4.6% (95% CI: 3.7–5.5%) for women. MAU
was present in 8.1% (95% CI: 6.9–9.3%) of the partici-
pants with hypertension, and in 11.4% (95% CI: 10.0–
12.8%) of those with diabetes, with the prevalence in each
of these subgroups significantly higher than in subgroups
Table 2 24-h urinary albumin excretion (mg/d) and prevalence of microalbuminuria (%, 95% CI) by selected risk factors
24-h urinary albumin excretion (mg/d) Microalbuminuria P value
N Mean P5 P25 P50 P75 P95 % (95% CI)
Total 1980 10.5 2.9 4.5 6.1 8.7 24.9 4.1 (3.2-5.0) -
Gender
Men 1038 10.4 2.9 4.4 6.0 8.5 24.6 3.7 (2.9-4.5) 0.32
Women 942 10.7 3.0 4.6 6.2 8.9 26.2 4.6 (3.7-5.5)
Age (years)
18 ~ 29 499 8.7 2.4 4.3 5.7 8.3 22.9 3.0 (2.2-3.8) 0.49
30 ~ 39 500 10.1 3.2 4.7 6.1 8.9 24.3 4.6 (3.7-5.5)
40 ~ 49 385 11.8 3.0 4.6 6.1 8.8 26.7 3.9 (3.0-4.8)
≥50 596 11.5 2.9 4.5 6.3 8.9 28.7 4.7 (3.8-5.6)
BMI
Low weight 70 9.0 2.4 4.1 5.1 7.2 13.3 1.4 (0.9-1.9) 0.10
normal 885 9.7 2.8 4.4 6.0 8.4 21.0 3.5 (2.7-4.3)
overweight 670 10.2 3.0 4.4 6.1 8.8 25.1 3.9 (3.0-4.8)
obese 353 13.4 3.1 5.0 6.7 10.1 53.3 6.2 (5.1-7.3)
Current smoker
Yes 517 10.4 2.8 4.2 5.7 8.2 24.2 3.5 (2.7-4.3) 0.42
No 1463 10.6 3.0 4.6 6.2 8.9 25.1 4.3 (3.4-5.2)
Hypertension
Yes 468 15.5 3.2 4.8 6.7 10.8 50.2 8.1 (6.9-9.3) <0.0001
No 1512 9.0 2.8 4.4 6.0 8.2 19.4 2.8 (2.1-3.5)
Diabetes,%
Yes 123 18.1 3.2 5.3 7.6 11.3 68.2 11.4 (10.0-12.8) <0.0001
No 1857 10.0 2.9 4.5 6.0 8.6 22.9 3.6 (2.8-4.4)
High TC,%
Yes 78 10.6 3.2 5.0 6.5 9.4 40.8 7.7 (6.5-8.9) 0.10
No 1902 10.5 2.9 4.5 6.0 8.7 24.6 3.9 (3.0-4.8)
High LDL,%
Yes 15 8.6 2.1 3.8 7.9 9.7 30.0 6.7 (5.6-7.8) 0.62
No 1965 10.5 2.8 4.5 6.1 8.7 24.8 4.1 (3.2-5.0)
Low HDL,%
Yes 224 13.3 2.8 4.6 6.1 9.6 26.9 4.9 (3.9-5.9) 0.51
No 1756 10.1 2.9 4.5 6.1 8.7 24.8 4 .0(3.1-4.9)
High TG,%
Yes 265 12.3 3.1 4.8 6.4 10.0 35.0 6.0 (5.0-7.0) 0.10
No 1715 10.2 2.8 4.5 6.0 8.6 23.5 3.8 (3.0-4.6)
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(Table 2). The prevalence of MAU in participants
with both hypertension and diabetes was 15.6% (95% CI:
14.0–17.2%).
The prevalence of MAU increased with the duration
of hypertension (Ptrend = 0.03). Relative to median dis-
ease duration (3 years), the prevalence of MAU was 8.7%
(95% CI:7.5–9.9%) in subjects with hypertension <3 yearsand 12.5% (95% CI:11.0–14.0%) in subjects with hyper-
tension >3 years (Figure 1).
Among the participants not receiving anti-hypertensive
treatment, there were linear trend relationships between
the prevalence of MAU and SBP (Ptrend = 0.003) and DBP
(Ptrend < 0.0001) levels (Figure 2).
The prevalence of MAU increased with numbers of
cardiovascular risk factors (Ptrend < 0.001). Its prevalence
Figure 1 Unadjusted prevalence of microalbuminuria (%, 95% CI) by duration of hypertension.
Figure 2 Unadjusted prevalence of microalbuminuria (%) by SBP and DBP levels in the participants not treated with anti-hypertensive
drugs. a. Unadjusted prevalence of microalbuminuria by SBP level (<110 mmHg, 110-119 mmHg, 120-129 mmHg, 130–139 mmHg, ≥140 mmHg)
in participants not treated with anti-hypertensive drugs. The rates of MAU (%, 95% CI) in these groups were 2.6% (95% CI: 1.9–3.3%), 3.1% (95% CI:
2.3–3.9%), 2.5% (95% CI: 1.8–3.2%), 6.2% (95% CI: 5.1–7.3%), 6.3% (95% CI: 5.2–7.4%). b. Unadjusted prevalence of microalbuminuria by DBP level
(DBP < 80 mmHg, 80-89 mmHg, 90-99 mmHg, ≥100 mmHg) in the participants not treated with anti-hypertensive drugs. The rates (%, 95% CI) of
MAU in these groups were 2.3% (95% CI: 1.6–3.0%), 4.3% (95% CI: 3.4–5.2%), 6.7% (95% CI: 5.6–7.8%), 10.1% (95% CI: 8.8–11.4%).
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obesity or dyslipdaemia was 2.6% (95% CI: 1.9–3.3%),
whereas its prevalence in the participants with >3 risk
factors was 9.8% (95% CI: 8.5–11.1%) (Figure 3).
Agreement between albuminuria assessed by measuring
of UAE and ACR
Table 3 shows the agreement between the prevalence of
albuminuria as determined by measuring of UAE and
ACR. The overall k index was 0.86 (95% CI: 0.80–0.91).
Risk factors for 24-h UAE and microalbuminuria
Linear regression analysis indicated that smoking, BMI,
SBP and LDL-C were independently associated with the
log(n)UAE. BMI and SBP were positively associated with
UAE, while smoking and LDL-C were negatively associ-
ated (Table 4).
Multiple logistic regression analysis showed that SBP
and FBG were independent risk factors for the develop-
ment of MAU, FBG was the most important risk factor
for MAU progression, with an odds ratio [OR] of 1.19
(95% CI: 1.05–1.35) (Table 5).
Discussion
Albuminuira, a component of the increasing disease
burden of chronic kidney disease in China, has been
a public health concern. This survey of community-
dwelling Chinese adults aged 18 to 69 years and liv-
ing in Shandong Province found that 4.1% had MAU,
as defined by 24-h UAE, with MAU being more
prevalent in the subjects with hypertension (8.1%) and
diabetes (11.4%). Disease duration, blood pressure and
serum glucose level were associated with MAU; there-
fore, both blood pressure and glucose should be con-
trolled as much as possible to prevent the progression
of MAU.Figure 3 Unadjusted prevalence of microalbuminuria (%, 95% CI) by
hypertension, diabetes, dyslipidaemia and obesity.The prevalence of MAU in Shandong adults was lower
in other regions in China (4.5–15%) [12,24-26]. This dis-
crepancy may be associated with geographic regional dif-
ferences or the characteristics of the sampled population
(e.g. age and cardiovascular disease profiles). In addition,
MAU was defined in our study by 24-h UAE, whereas in
other studies, MAU was defined by ACR or UAC. These
measurements were moderately correlated and were
comparable in predicting for cardiovascular disease mor-
tality in prospective studies [17]. We observed substan-
tial agreement of MAU classifications by measuring
UAE and ACR in the same timed 24-h urine samples.
However, there were still systematic differences in the
classification of albuminuria prevalence [27]. Validation
studies are required to determine the correlation be-
tween MAU as determined by 24-h UAE, as determined
by ACR or UAC from untimed spot urine samples in
Chinese population.
In agreement with previous studies, we found that
hypertensive individuals were at high risk for MAU, with
blood pressure linearly associated with MAU [12,24,28,29].
A recent national hypertension survey in China found that
blood pressure was controlled under 140/90 mmHg in
9.3% of hypertensive individuals [30]. In comparison, we
found that blood pressure was controlled in 14.9% hyper-
tensive adults in Shandong Province [18]. Uncontrolled
blood pressure may increase the risk of MAU progression.
Recent hypertension management guideline have recom-
mended that patients of any age with MAU initiate
pharmacologic treatment to lower blood pressure [8].
Therefore, more aggressive preventive and/or treatment
strategies are needed to control blood pressure in hyper-
tensive patients with MAU.
MAU is the first sign of diabetic nephropathy. The
percentage of our diabetic patients with MAU was much
lower than the previously reported prevalence in Chinanumber of cardiovascular disease risk factors, including
Table 3 Agreement of albuminuria defined by 24 h urinary albumin excretion and 24 h albumin to creatinine ratio







No. % No. % No. %
Normal <30 mg/g 1882 99.2 7 8.6 0 0 0.86 (0.80-0.91)
Microalbuminuria 30-299 mg/g 15 0.8 72 88.9 0 0
Macroalbuminuria ≥300 mg/g 0 0 2 2.5 2 100.0
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was associated with disease duration [34]. Previous stud-
ies, however, usually included hospital-based patients or
those with diabetes, with most of these subjects being
patients with a history of diabetes. In contrast, most
(70%) of the diabetic patients participated in our study
were initially diagnosed in this survey. Furthermore,
those previously diagnosed had a relative short disease
duration (average 2.4 years).
We also found that MAU was associated with obesity
and dyslipidemia [35,36], with the prevalence of MAU
strongly related to the number of established cardiovascu-
lar disease risk factors. The Metabolic Syndrome—a cluster
of the risk factors including elevated blood pressure, fasting
blood glucose, BMI and serum cholesterol—was shown to
be a predictor of MAU progression, and eventually of overt
proteinuira and chronic kidney disease [37,38].
The utility of albuminuira screening in the general
population is unclear [12,14,39-42]. Despite its predictive
value for end-stage kidney disease, cardiovascular disease
and death, several factors influence the potential imple-
mentation of MAU screening in clinical practice, includ-
ing the prevalence of MAU in the target population, the
type of test performed, the threshold for albuminuria
and the cost of screening [39-42]. Results from the Third
National Health and Nutrition Examination Survey find-
ing in the United States estimated that screening of 11
(95% CI: 10–12) adults was required to identify one indi-
vidual with MAU [14]. Our finding in adults from the
Shandong Province suggested that 24 (95% CI: 20–30)
adults would have to be screened to identify one withTable 4 Linear regression analysis of 24 h urinary
albumin excretion with related covariates*
Covariates β P value
Smoking (yes/no) −0.0008 0.02
BMI (kg/m2) 0.0165 0.0001
SBP (mmHg) 0.0043 <0.0001
LDL-C (mmol/l) −0.0814 0.002
*: log(n) UAE was used as the dependent variable in the linear regression model,
with the stepwise method used for selection of variables. The selected
variables included age, gender, smoking (yes/no), BMI, SBP (mmHg), FBG (mmol/l),
TC (mmol/l), HDL-C (mmol/l), LDL-C (mmol/l) and TG (mmol/l).MAU. Studies are needed to determine the value of
screening for MAU in the general Chinese population.
A major strength of our study was our use of the gold
standard 24-h UAE to classify individuals with microalbu-
minuria, unlike previous studies in Chinese populations.
Furthermore, this study included a representative sample
of the general population, using rigorously standardized
methods for data collection and strict quality control. How-
ever, our study has several limitations. First, we collected
only one 24-h urine sample per participant, thus preventing
a determination of day-to-day variability for each individual
[43]. Second, the completeness of 24-h urine collection was
assessed by measuring urinary volume and creatinine
concentration. Without an objective measure such as
p-aminobenzoic acid (PABA), it is difficult to assess the
completeness of urine collection [44]. Third, serum cre-
atinine was not measured in our study, therefore, we were
unable to determine glomerular filtration rate or the preva-
lence of chronic kidney disease. Fourth, our study popula-
tion included only adult residents of Shandong Province,
thus limiting the applicability of our results to other popu-
lations. Finally, owing to the cross-sectional nature of
this study, we were unable to quantify the associations
betweenhypertension and diabetes and the progression of
MAU. Follow-up studies are therefore recommended.
Conclusions
This study showed that the prevalence of MAU in the
general adult population of Shandong Province, China,
is moderate. Rates of MAU were higher in subjects with
than without hypertension and diabetes, with these two
factors together associated with MAU. Screening of sub-
jects with hypertension and/or diabetes for MAU may
result in earlier diagnosis and treatment.Table 5 Multiple logistic regression analysis of
microalbuminuria with related covariates*
Covariates OR (95% CI) P value
SBP (mmHg) 1.02 (1.01-1.03) <0.001
FBG (mmol/L) 1.19 (1.05-1.35) 0.006
*: Stepwise method was used for the variable selection. The selected variables
included age, gender, smoking (yes/no), BMI, SBP (mmHg), FBG (mmol/l),
TC (mmol/l), HDL-C (mmol/l), LDL-C (mmol/l) and TG (mmol/l).
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